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Abstract
Surfactant protein A (SP-A) is a highly ordered, oligomeric glycoprotein that is secreted into the airspaces of the lung by
the pulmonary epithelium. The in vitro activities of protein suggest diverse roles in pulmonary host defense and surfactant
homeostasis, structure and surface activity. Functional mapping of SP-A using directed mutagenesis has identified domains
which interact with surfactant phospholipids, alveolar type II cells and microbes. Recently developed genetically manipulated
animal models are beginning to clarify the critical physiological roles for SP-A in the normal lung, and in the
pathophysiology of pulmonary disease. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
The alveolar surface of the lung is a vulnerable
biological interface, subject to destabilizing surface
forces that promote airspace collapse, and to contin-
uous bombardment by inhaled particulates, patho-
gens and toxins. The survival of air breathing organ-
isms is dependent on the presence of a multi-
functional pulmonary epithelial lining substance
called surfactant [1]. Surfactant is an oily mixture
of proteins, phospholipids and neutral lipids that is
secreted by alveolar type II cells and organized as a
layer (or layers) at the air^liquid interface. The sur-
factant ¢lm both reduces surface pressures and ac-
tively participates in the clearance of foreign materi-
al. The most critical component of surfactant for
airspace stability is dipalmitoylphosphatidylcholine
(DPPC), a saturated phospholipid which accounts
for virtually all of surfactant’s surface tension low-
ering properties. Two hydrophobic surfactant pro-
teins, surfactant protein B (SP-B) and surfactant pro-
tein C (SP-C), are critical for the adsorption and
spreading of the surfactant ¢lm at the air^liquid in-
terface (Chapter IX). Surfactant protein D, on the
other hand, has in vitro activities that suggest a pri-
mary role in host defense (Chapter XV). The most
abundant surfactant protein, surfactant protein A
(SP-A) was ¢rst identi¢ed by King and Clements in
1972 [2]. Despite early discovery and intense inves-
tigation, the function of SP-A is perhaps the most
controversial of the four surfactant proteins. Most
studies have focused on the role of SP-A in surfac-
tant structure and function, but there is increasing
evidence that SP-A participates in pulmonary host
defense. In this chapter, the structure and processing
of SP-A will be reviewed and compared with other
members of the collectin family of related proteins.
The biochemical properties of SP-A will also be dis-
cussed, especially as they relate to alveolar type II
cell and surfactant phospholipid interactions, with
an emphasis on structure^function relationships.
The host defense properties of SP-A will only be
mentioned in the context of known structure^func-
tion relationships as they relate to binding, opsoni-
zation and clearance of microorganisms. For a more
detailed discussion of the innate immune properties
of SP-A, the reader is referred to Chapters XII and
XIII.
2. Structure
2.1. Overview of SP-A structure and assembly
Surfactant protein A has been found in every ver-
tebrate species that has been carefully examined, in-
cluding in the lungs and swimbladders of some spe-
cies of lung¢sh and gold¢sh [3,4]. Sequence
comparison of the cDNAs for SP-A isolated from
human [5], dog [6], rabbit [7], guinea pig [8], rat [9]
and mouse [10] reveal extensive homology. The de-
duced primary structure of SP-A is characterized by
four well de¢ned structural domains (Fig. 1): a short
N-terminal segment containing interchain disul¢de
BBADIS 61766 30-10-98
F.X. McCormack / Biochimica et Biophysica Acta 1408 (1998) 109^131110
bonds, a proline-rich collagen-like region, a hydro-
phobic ‘neck’ domain and a carbohydrate recogni-
tion domain (CRD) with bears a high degree of ho-
mology to several members of the Ca2-dependent
(C-type) mammalian lectins, especially mannose
binding protein A (MBP-A) [11]. The combination
of a collagen-like region and a C-type lectin domain
are the de¢ning structural features of the emerging
collectin family of proteins, many of which have been
shown to function as antibody independent opsonins
[12]. In addition to SP-A, the other collectins include
MBP-A [11], bovine conglutinin [13], CL-43 [14], and
SP-D [15].
Surfactant protein A is recovered from the airspa-
Fig. 1. Monomeric and oligomeric structure of SP-A. The deduced primary structure of SP-A predicts four major structural domains:
a short N-terminal segment containing two intermolecular disul¢de bonds, a collagen-like sequence of gly^x^y repeats, an acidic and
hydrophobic neck domain and a C-terminal carbohydrate recognition domain. The neck domains of three SP-A monomers become as-
sociated as rigid K-helical coiled coils and the collagen-like regions fold into staggered collagen triple helices. Six trimeric subunits
form the fully assembled, octadecameric molecule, which is stabilized by disul¢de linkages in the N-terminal domains.
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ces of the lung by bronchoalveolar lavage. High-
speed centrifugation of the lavage £uid sediments
SP-A complexed with surfactant phospholipids. SP-
A is most commonly puri¢ed from the pellet by bu-
tanol extraction [16] followed by adsorption to a
monosaccharide-linked a⁄nity matrix and size-frac-
tionation by gel exclusion chromatography [41]. Pu-
ri¢ed SP-A migrates heterogeneously on SDS^PAGE
under reducing conditions [17], due largely to varia-
ble glycosylation with sialic-acid containing complex
carbohydrates at one [18] (human, dog, rabbit) or
two (guinea pig, mouse and rat) [17,18] potential
asparagine attachment sites. Under nonreducing con-
ditions, the protein appears as a ladder of disul¢de-
linked multimers composed of up to six or more
subunits [16,17].
Based on analogy with other collectins, the folding
of SP-A in the endoplasmic reticulum likely proceeds
from the C-terminal to N-terminal direction in a
zipper-like fashion [19,20]. These studies predict
that globular CRDs fold separately while the more
N-terminal domains, the collagen-like region and the
neck, become associated as trimeric helices [21]. The
neck domain of SP-D forms a triple stranded K-hel-
ical nonstaggered bundle that functions as the nucle-
ation site for the folding of the collagen-like domain
into staggered triple helices [22]. The formation of
collagen-like triple helices in SP-A is supported by
circular dichroism studies [23^25], but the folding
of the neck region has not been directly examined.
The formation of N-terminal intermolecular disul¢de
bonds in SP-A probably occurs last, as it does in SP-
D, after the folding of the collagen region is com-
pleted [20].
The apparent molecular mass of human SP-A in
solution is reported to be 650 kDa by gel ¢ltration
analysis and sedimentation equilibrium studies [23],
indicating the association of six trimers. Under the
electron microscope, SP-A has a highly ordered
structure that resembles a bouquet of tulips [25].
Taken together, the available data are consistent
with an hexagonal, in-register array of trimeric units,
which are laterally bound by strong hydrophobic
(van Der Waals) forces and charged interactions
through the ¢rst half of the collagen-like domain,
and stabilized by inter- and intra-trimeric disul¢de
bonds at the N-terminus (Fig. 1) [25]. This structure
is very similar to that of C1q (which is not a collec-
tin) [26] and MBP-A. The collectins with more elon-
gated collagen-like regions either form cruciform
structures (SP-D and conglutinin) or simple trimers
(CL-43 and MBP-C).
2.2. Comparative structure of individual domains of
SP-A
2.2.1. The N-terminal segment
The N-terminal segment of SP-A is 8^11 amino
acids in length, depending on the species and varia-
tion in N-terminal processing (see below). There are
two Cys residues present in this region in SP-A from
all species examined except dog, which contains only
one. Both Cys have been shown to participate in
interchain disul¢de bond formation in rat SP-A,
and to be required for multimer formation [27].
The pattern of disul¢de linkage is most likely a sym-
metrical 1^1, 2^2 pattern, based on the elution pat-
tern during N-terminal protein sequence analyses.
There are also two Cys present in the N-terminal
segment of all other collectins [12] but in the case
of MBP-C disul¢de bridges appear to be asymmet-
rical and heterogeneous (1^1, 2^2, 1^2 or 1^2, 1^2,
1^2) [28]. There are several highly conserved charged
and hydrophobic amino acids £anking the second
Cys in the SP-As from di¡erent species, but the N-
terminal segment does not bear any signi¢cant ho-
mology to the other collectins or to other proteins in
GenBank. The interchain disul¢de bond formed by
the Cys adjacent to the collagen-like region of rat
SP-A (Cys6) has been shown to be required for in-
teractions with surfactant lipids and alveolar type II
cells [29] (see below), but preliminary data indicate
that the more N-terminal Cys31 is not critical for
these functions [30].
2.2.2. The collagen-like region
The collagen-like region of SP-A contains a series
of 23 (human,baboon) or 24 (rat, rabbit, dog, guinea
pig) gly^x^y repeats. The deduced primary structures
of human and rat cDNAs predict Pro in the x posi-
tion of 4 or 5 of the repeats, clustered near the mid-
point and the C-terminal end of the collagen domain.
Prolines are also predicted in the y position of 15 or
16 of the repeats, most or all of which are hydroxy-
lated based on partial N-terminal protein sequencing
analysis [9]. The presence of hydroxyproline in colla-
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gens greatly enhances the stability of the collagen
helix [31]. The ¢rst half of the collagen-like domain
of SP-A, which is the most highly conserved region
in the molecule, contains a series of alternately pos-
itively and negatively charged amino acids (+/3,
+/3). This charge pattern is conserved in the other
collectins as well, except that Gln occupies the sec-
ond ‘positive’ position in CL-43. There are also alter-
nating charged amino acids in the second half of the
collagen domain of SP-A, but the order is reversed
(3/+, 3/+). These charged segments may contribute
to the stability of the triple helix, to binding to a
common collectin receptor [32], and/or to association
of SP-A with soluble ligands [33^35]. The two
charged motifs are separated by an interruption in
the reiterative tripeptide sequence after the 12th re-
peat. This ‘hinge region’ introduces a visible 60‡ bend
into the collagen domain which tilts the globular
heads away from the core in the fully assembled
molecule [25]. An interruption in the collagen region
of the structurally related molecule C1q also intro-
duces a bend into the domain [36], but a similar
break in the collagen sequence in MBP-A not pro-
duce any obvious structural change [37]. The other
known collectins contain continuous collagen-like re-
gions. The collagen-like domain is important for
binding to at least one known SP-A receptor [38]
and for speci¢c inhibition of surfactant secretion
from isolated type II cells [29], but it is not yet clear
if the collagen region participates in direct protein^
protein interactions or whether it is primarily a scaf-
folding that ampli¢es the ligand binding activities of
other domains of the molecule (e.g., the CRD).
2.2.3. The neck region
Constructs composed of the neck+CRD of SP-A
are trimeric in solution, based on crosslinking studies
(F. McCormack, unpublished observations) and gel
exclusion chromatography [24]. Like all collectins,
the stretch of 38^40 amino acids between the colla-
gen-like region and the lectin domain of SP-A con-
tains hydrophobic amino acids that can be roughly
organized into heptad repeats. It is very likely that
the polypeptide strands in the neck region of SP-A
fold separately into rigid K-helical coils that are non-
covalently associated by strong hydrophobic (van
Der Waals) forces, as does the corresponding region
of SP-D [22], although this has not been directly
examined. This model predicts two hydrophobic
faces of each SP-A polypeptide chain that are poten-
tial association domains for adjacent chains, and
four faces containing charged and polar residues
that are directed toward the solvent. There are two
highly conserved positively charged residues at the
midpoint of this otherwise very acidic region (e.g.,
His95, Lys96 in rat SP-A). In addition to its critical
role in protein folding, the neck domain may orient
the CRDs of SP-A trimers for selective ligand bind-
ing. The solution of the structure of the MBP-A
trimer revealed that each CRD is spaced approxi-
mately 50 Aî from the other two [21]. Hydrophobic
amino acids at the C-terminal end of the neck do-
main of MBP-A form the interface with the CRD,
and sequence variations in this region of the collec-
tins may play a role in determining the alignment of
the CRDs [21]. There is some evidence that cooper-
ative interactions between the neck and CRD con-
tribute to SP-A interactions with type II cells [39],
but it is not clear if the neck domain of SP-A has any
direct ligand binding roles.
2.2.4. The carbohydrate recognition domain
The CRDs from animal lectins can be broadly
classi¢ed into those that preferentially bind galactose
or N-acetylgalactosamine and those that bind man-
nose or N-acetylglucosamine [40]. The CRD of SP-A,
a member of the mannose subgroup, has been shown
to mediate a variety of interactions including modu-
lation of alveolar type II cell functions, binding and
aggregation of phospholipids, and non-immune rec-
ognition of bacterial, viral and fungal organisms.
This region contains approximately 115 amino acids
including four conserved Cys which form two intra-
molecular disul¢de loops, as well as 10 additional
invariant and 18 highly conserved amino acid resi-
dues common to the C-type lectins [41]. There are at
least two Ca2 binding sites in the CRD of SP-A
[42,43], and all reported CRD functions are Ca2-
dependent. There are only two tryptophans in the
CRDs of all species which have been characterized
to date [8], and both are located near the Ca2 bind-
ing sites predicted by comparison with the crystal
structure of MBP-A (see below). In this position
the tryptophans can be used as reporters to detect
conformational changes in the region. The binding of
Ca2 to the CRD of SP-A results in an increase in
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intrinsic £uorescence and a shift in the emission max-
ima toward shorter wavelengths, indicating translo-
cation of tryptophan to a more hydrophobic envi-
ronment [42,44]. This conformational shift enhances
resistance to protease digestion, probably by burying
potential protease cleavage sites in the core of the
protein [42]. Mutagenesis studies suggest that the
carbohydrate binding site of SP-A colocalizes with
a major Ca2 binding site [39,45,46], and that amino
acid substitutions that eliminate conformational
shifts also interfere with the karacteristic ligand bind-
ing functions of the CRD [46,47].
X-Ray crystallographic studies of the CRDs of
natural and mutant recombinant C-type lectins
have elucidated the intermolecular forces that deter-
mine carbohydrate binding in this protein family [48^
51]. The ¢rst C-type lectin and the only collectin
structure that has been solved is MBP-A complexed
with an asparaginyl oligosaccharide (Fig. 2) [52].
Analysis of the acceptor and ligand together clari¢ed
the relationship of atomic components of the penul-
timate mannose residue of the oligosaccharide to the
amino acids and Ca2 ions in the carbohydrate bind-
ing site of the protein [49]. The carbohydrate binding
site is located in a large loop that arises from a tight
core domain composed of two helices, two beta
strands and two beta sheets. The loop contains three
Ca2 binding sites, one located in the sugar binding
site (denoted #2 Ca2), and two located closer to the
origin of the loop (#1 and #3 Ca2). The #3 Ca2
binding site was thought to be artifactual. The dif-
fraction analysis revealed that the carbohydrate is
bound by network of Ca2 coordination bonds and
hydrogen bonds [40]. The #2 Ca2 ion was com-
plexed with oxygen atoms from the side chains of
Glu185, Asn187, Glu193, Asn205, and Asp206 (see Fig.
2). The 3P and 4P equatorial hydroxyl groups of man-
nose also formed Ca2 coordination bonds, as well
as hydrogen bonds with amine and carbonyl side
chains of Glu185, Asn187, Glu193 and Asn205. Subse-
quent site-directed mutagenesis studies con¢rmed
crystallographic evidence that van der Waals interac-
tions between sugar and the imidazole ring of His189
and carbon atoms of Ile207 also contributed to bind-
ing [53]. Thus, the binding of mannose to individual
CRDs of MBP-A is due to a collection of relatively
weak interactions. The a⁄nity of MBP-A for ligands
is greatly increased by the simultaneous binding of
multiple CRDs of each oligomer to the sugar, lipid
or protein target [54].
The solution of the structure of C-type lectin^oli-
gosaccharide complexes has also demonstrated that
carbohydrate binding speci¢city is determined by
structural characteristics of both the carbohydrate
and the protein [40,52]. Sugars exhibiting the pre-
ferred axial and equatorial arrangement of key hy-
droxyl groups ‘¢t’ into carbohydrate binding sites in
which carbonyl and nitrogen containing amino acid
side chains are presented in the correct context for
hydrogen bond formation. The C-type lectins which
bind to mannose prefer sugars with equatorial hy-
droxyl groups at the 3- and 4-positions of the hexose
ring, while lectins which bind galactose recognize
sugars with an axial 4-hydroxyl. Drickamer provides
elegant con¢rmation of the structural elements of
MBP-A that confer selectivity [55]. He noted that
C-type lectins which bind to mannose contain a con-
served Glu^Pro^Asn (EPN) sequence in the carbohy-
drate binding site of MBP-A, while related protein
family members that exhibit selective binding to gal-
actose contained a Gln^Pro^Asp (QPD) motif in the
corresponding region of the CRD. The construction
of a mutant recombinant MBP-A containing a QPD
substitution at the EPN locus converted the carbo-
hydrate binding preference from mannose to galac-
tose, as was predicted. Other structural features have
also been shown to play a role in the discrimination
between favored and unfavored ligands, such as
steric exclusion. Finally, the spatial arrangement of
multiple CRDs on the rod like sca¡olding of the
collectins enable them to bind speci¢cally to micro-
organisms. Solution of the trimeric structure of
MBP-A revealed that the spacing of the CRDs in
MBP-A precludes multivalent binding to a typical
mammalian high mannose oligosaccharides, but it
is optimal for avid binding to the repetitive sugar
arrays on the surfaces of pathogenic organisms [21].
3. Processing
3.1. Tissue distribution
There are two transcribed genes for human SP-A
on the long arm of chromosome 10 [56,57], which
encode isoforms containing minor amino acid di¡er-
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ences in the protein. The baboon also has two genes
[58], but only one gene has been found in all lower
species that have been examined. Surfactant protein
A mRNA and protein are expressed in epithelial cells
of the distal airspaces, including alveolar type II cells
and the nonciliated bronchiolar cells (Clara cells)
of the terminal bronchioles and conducting airways
(especially in rodents) [59,60]. SP-A mRNA is
also found in the serous glands of the proximal
human trachea [59]. Immunohistochemical staining
detects SP-A in the endocytic compartment of
macrophages but de novo synthesis does not occur
within the phagocyte. Western-blot analyses have
suggested the presence of SP-A in rat intestinal
epithelia [61], human and rat mesentery [62] and
human inner ear [63], although the precise identity
of the immunoreactive proteins has not been
determined.
3.2. Signal peptidase cleavage and N-terminal
processing
SP-A is synthesized as a preprotein with a leader
sequence of 17^28 amino acids, which is cleaved
from the nascent peptide as it is translocated into
the endoplasmic reticulum. Elhalwagi et al. recently
reported two alternative N-termini in rat SP-A, sug-
gesting heterogeneity in N-terminal processing [27].
They found that rat SP-A is composed of a short
variant that has the predicted N-terminus (Asn1^
Val^Thr^Val4), and a less abundant (approx. 20%)
variant that contains three additional amino acids at
the N-terminus, including an additional Cys (Ile33^
Lys^Cys31^Asn1^Val^Thr^Val4). Expression of a
full-length cDNA for rat SP-A in eucaryotic cells
resulted in the production of recombinant proteins
representing both variants, in the same 80:20 (short:
long) ratio that was observed for the natural SP-A.
This result indicated that a tissue-speci¢c protease
was not required for the alternative cleavage. Dele-
tion mutagenesis that varied the amino acid sequence
downstream of the cleavage region altered the abun-
dance of the short and long variants, consistent with
the known sensitivity of signal peptidase to the con-
text of the amino acid sequence near the cleavage
site. Collectively, the data suggests that N-terminal
microheterogeneity arises by di¡erential use of alter-
native signal peptidase cleavage sites.
Human SP-A also has variable N-termini [27], in-
cluding two cysteinyl variants, but SP-A from other
species has not been examined. The identi¢cation of
a second Cys at the N-terminus of SP-A is consistent
with the primary structure of the other collectins that
have been described to date, which all have two N-
terminal Cys [12]. The structural features of the lead-
er sequence and N-terminal sequence that lead to
alternative cleavage are not known, but possibilities
include cotranslational disul¢de bond formation at
Cys 31 of the nascent peptide or the use of alterna-
tive translation initiation sites (Met-20 or Met3-29 in
rat SP-A). Another protein which has been shown to
exhibit microheterogeneity due to alternative signal
peptidase cleavage at the N-terminus is interferon g1
[64], a recently discovered protein with an unknown
physiological function that is structurally related to
interferon K and L. Interestingly, like SP-A, this mol-
ecule also contains Cys residue near the primary
Fig. 2. The Ca2 and carbohydrate binding site of MBP. X-
Ray di¡raction analysis of an MBP-A^asparaginyl oligosacchar-
ide complex revealed the relative positions of Glu 185, Asn
187, Glu 193, Asn 205 and Asp 206 of the carbohydrate bind-
ing site of the CRD of MBP-A, a Ca2 ion and the terminal
mannose residue of the ligand. The Ca2 ion is anchored by co-
ordination bonds with oxygen atoms from all ¢ve amino acids.
The 3- and 4-hydroxyl groups of the mannose residue are
bound by Ca2 coordination bonds and hydrogen bonds with
amine and carbonyl side chains of Glu 185, Asn 187, Glu 193
and Asn 205. Not shown are hydrophobic interaction between
the sugar and His 189 and Ile 207. The Ca2 and carbohydrate
binding site of SP-A is modeled based on the MBP structure.
(Drawing from Ref. [49].)
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cleavage site and a second, in-frame methionine in
the leader peptide which might potentially function
as a second translation initiation site. Di¡erential use
of alternative translation initiation sites as a mecha-
nism to regulate expression of protein isoforms has
been described [65].
3.3. Post-translational modi¢cation, sorting and
tra⁄cking
After synthesis, SP-A is extensively modi¢ed in the
rough endoplasmic reticulum (ER) and Golgi, in a
sequence that appears to parallel that of the ¢brillar
collagens [31]. Mammalian collagens are hydroxy-
lated [23,67] in the endoplasmic reticulum by prolyl
hydroxylase [68], a heterotetrameric enzyme com-
posed of K and L subunits (K2L2) that catalyzes the
formation of 4-hydroxyproline. This enzyme also
catalyzes strand alignment and the assembly of thi-
ol-dependent multimers through the activity of its L
subunit, which has been found to be identical to the
enzyme protein disul¢de isomerase [69]. Most of the
folding and assembly of SP-A occurs before the pro-
tein exits the endoplasmic reticulum (ER). SP-A is
also cotranslationally glycosylated with mannose-
rich, endoglycosidase H (endo H) sensitive carbohy-
drates in the ER. The acquisition of endo H resist-
ance is used as a marker of entry of SP-A into the
Golgi apparatus [18]. Late post-translational carbo-
hydrate modi¢cations in this organelle include
sialylation [16] and sulfation [66], which contribute
to charge heterogeneity of the molecule on electro-
phoretic analysis. The complex folding, assembly and
processing of SP-A likely contributes to the relatively
slow rate at which SP-A traverses the secretory path-
way [70].
The structural requirements for proper tra⁄cking
have been explored using metabolic inhibitors and
heterologous expression of recombinant proteins in
eucaryotic cells. N-Linked carbohydrate is not re-
quired for intracellular tra⁄cking, since elimination
of N-linked glycosylation sites [71] or incubation
with speci¢c inhibitors of glycosylation [18,72] do
not block secretion of the protein. Secretion from
eucaryotic cells is preserved despite genetic disrup-
tion of either N-terminal interchain disul¢de bond
of rat SP-A [29,30], but blocking disul¢de bridge
formation at both locations results in intracellular
retention (F. McCormack, unpublished observation).
Inhibition of hydroxylation or incorporation of cis
hydroxyproline results in accumulation of SP-A in
the endoplasmic reticulum, presumably due to dis-
rupted assembly of the SP-A multimer [70,72]. How-
ever, underhydroxylation of the collagen region that
occurs when recombinant SP-A produced in inverte-
brate cells does not block secretion [71]. Similarly,
partial or complete deletion of the collagen-like re-
gion does not prevent secretion from insect cells [29]
or mammalian (CHO) cells (F. McCormack, unpub-
lished observation). Interestingly, the removal of the
collagen-like region appears to relax the secretory
requirement for interchain linkage, since a construct
containing only the neck and CRD of SP-A (SP-
AvN1ÿP80) is secreted from insect cells despite the
absence of intermolecular disul¢de bonds [27]. Muta-
tions of the neck region of SP-A are generally poorly
tolerated. Point substitutions, partial deletions and
chimeric substitutions of the neck region with corre-
sponding portions of other collectins typically results
in rapid intracellular degradation and/or retention
(F. McCormack, unpublished observation), probably
re£ecting the importance of this domain in the or-
chestration of protein folding. In contrast, more than
15 CRD mutant SP-As, including those containing
point mutations in Ca2 and carbohydrate coordi-
nating residues [46,73] and large substitutions span-
ning the putative lipid and carbohydrate ligand bind-
ing domains [74,75], traverse the secretory pathway
and can be recovered from the extracellular compart-
ment. There are some exceptions; for example, dele-
tion of the Cys204^Cys218 region of rat SP-A caused
the protein to be retained [39]. These data provide
evidence that N-terminal interchain linkage and a
properly folded collagen-like domain are required
for proper intracellular routing, but N-linked oligo-
saccharides and the integrity of the CRD may be less
critical for tra⁄cking of SP-A through the secretory
pathway.
Surfactant phospholipids and the hydrophobic
surfactant proteins exit the Golgi and are routed
through the multivesicular body to the lamellar
body [76]. In response to the appropriate stimulus,
they are secreted together in a regulated fashion.
Although small amounts of SP-A are found in the
periphery of lamellar bodies by immunoelectronmi-
croscopy [77], it is not clear that SP-A reaches the
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lamellar body by the biosynthetic route as do the
other surfactant components. In fact, the lopsided
distribution of SP-A between the extracellular and
intracellular surfactant compartments suggests that
SP-A is secreted through a pathway that bypasses
the lamellar body. SP-A makes up approx. 50% of
total protein in isolated surfactant but only about 1%
of total protein in lamellar bodies [78], which corre-
lates with the abundance of SP-A in tubular myelin
and paucity of SP-A in lamellar bodies detected by
immunoelectron microscopy [79]. Metabolic labeling
studies also support the existence of a second path-
way. In preterm ventilated lambs pulsed with 35S,
SP-A appears in lavage £uid but not in LB in the
¢rst 2 h, and then gradually appears in the lamellar
body [80]. It is possible that SP-A is secreted into the
alveolar space by at two or more routes; via a regu-
lated pathway that includes the lamellar body and a
constitutive pathway that bypasses that compartment
[80,81]. Alternatively, newly synthesized SP-A may
be directly secreted and all SP-A within the lamellar
body may reach the organelle by endocytosis of sur-
factant components from the extracellular space.
4. Properties
4.1. Background
Formulation of hypotheses about the functions of
SP-A (Table 1) have been largely based on: (1) ho-
mologies with other proteins such as MBP-A, (2)
ligand binding properties (Table 2) and measurable
in vitro ‘biological’ activities (Table 3), (3) analyses
of SP-A in pathological states in humans and exper-
imental animals, and most recently (4) phenotypic
characterization of genetically engineered animal
models. There have been no reports of naturally oc-
curring mutations in SP-A, such as those that have
been useful in characterizing the function of other
lung proteins (e.g., K1-antitrypsin, CFTR). The ¢rst
decade of SP-A research was focused primarily on
the role of the protein in surfactant homeostasis
Table 1
Putative biological functions of SP-A
Surfactant homeostasis
Receptor-mediated inhibition of surfactant secretion from
type II cells [118^120]
Receptor-mediated enhanced uptake of surfactant phospholipids
by type II cells [152,153]
Surfactant biophysical activity
Enhanced phospholipid adsorption to the monolayer [109]
Prevention of protein inhibition by proteinaceous pulmonary
edema [84,107,108]
Maintenance of surfactant aggregate structure, especially
tubular myelin [83,99]
Maintenance of pool of surface active, large (dense) surfactant
aggregates [84,100,103]
Phospholipase A2 inhibition [148,149]
Scavenger functions in alveolar hypophase
Myosin clearance [151]
Lipopolysaccharide clearance and/or regulation of activity
[33,34]
Host defense functions
Microbial binding and aggregation [47,87,154,155]
Macrophage activation and chemotaxis [156^160]
Enhanced microbial phagocytosis and killing
[82,87,122,158,161^163]
Antiproliferative and antiin£ammatory e¡ects on lymphocytes
[35,164,165]
Table 2
Biological ligands for SP-A
Surfactant phospholipids [111,166,167]
Dipalmitoylphosphatidylcholine
Phosphatidylcholine
Sphingomyelin
Pulmonary glycolipids [98,168]
Lactosylceramide
Galactosylceramide
Glucosylceramide
Asialo-GM2
Proteins
Phospholipase A2 [147^149]
Major surface glycoprotein of P. carinii [47,88]
Outer membrane protein of H. in£uenza [87]
Myosin [151]
Annexin IV [150]
SP-A receptors:
210 kDa SP-R (Chroneos) [38]
32 kDa SPAR (Strayer) [124,126,169]
126 kDa C1qRp (Nepomuceno) [130]
53 kDa C1qR (Malhotra) [131]
55 kDa BP55 (Wissel, Stevens) [127,128]
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and function, with a lesser emphasis on the putative
host defense properties of the protein. For many
laboratories, the prioritization of these two lines of
lines of investigation has become inverted in the past
several years, in part due to evidence of an immune
defect in the SP-A knockout mouse ([82,83]; see
Chapter XVI). Recent evidence of subtle surfactant
dysfunction in this model suggests that SP-A will
ultimately prove to have both surfactant and antimi-
crobial functions [84], the relative importance of
which will become increasingly apparent as these
and other genetically engineered animal models are
more completely characterized. Other chapters in this
series will address the host defense roles of SP-A
(Chapter XIII) and the interactions of SP-A with
phagocytes and epithelial cells (Chapter XII). The
discussion below will therefore focus primarily on
the relationships between the structure and function
of SP-A, especially in the context of interactions with
surfactant lipids and alveolar type II cells.
4.2. Binding of SP-A to monosaccharides and sugars
associated with glycoproteins and glycolipids
The carbohydrate recognition domain of SP-A me-
diates the selective recognition of pathogenic organ-
isms and the binding to several soluble and mem-
brane-associated ligands. The lectin activity of SP-
As was ¢rst suggested by Drickamer et al. [11], based
on that observation that SP-A C-terminal sequences
were 30% identical with rat MBP-A [5]. Haagsman et
al. subsequently con¢rmed that SP-A binds to a va-
riety of monosaccharide ligands, including mannose,
glucose, galactose and L-fucose, via the C-terminal
domains of the protein [85]. Better assessment of
the selectivity of SP-A for sugars was obtained using
a solid phase enzyme-linked lectin binding assay [86].
The ability of various monosaccharides to compete
for binding of SP-A to mannan, a yeast-derived
polymer of mannose, was found to follow the
rank order: N-acetylmannosamines L-fucose, malt-
oses glucosesmannose. Galactose, D-fucose, glucos-
amine, mannosamine, galactosamine, N-acetylglucos-
amine and N-acetylgalactosamine did not inhibit
mannan binding. This pattern of ligand preferences
was very similar to MBP-A, except that binding
of MBP-A to mannan was strongly inhibited by
N-acetylglucosamine.
Because there is no three-dimensional structural
data available for SP-A, MBP-A is used as a model
for SP-A^carbohydrate interactions. The amino acids
Glu195, Arg197, Glu202, Asn214 and Asp215 of rat SP-A
correspond to the MBP-A coordination set for Ca2
and carbohydrate binding. Alanine substitutions for
each of these residues reduced the binding to both
Table 3
Reported in vitro activities of SP-A
Ca2-dependent self-aggregation [170]
Carbohydrate binding to simple sugars and polysaccharides
[85,86]
Lipid binding
Ca2-dependent lipid aggregation [167,171]
pH-dependent lipid aggregation [46,172]
Enhanced surface activity of surfactant ¢lms [109]
Reduced inhibition of surfactant activity by foreign proteins
[107,108]
Reconstitution of tubular myelin from surfactant components
[99]
Inhibition of conversion of large to small surfactant aggregates
[100,103]
PLA2 inhibition [147^149]
Type II cell receptor binding [173^175]
Self internalization into type II cells [176,177]
E¡ects on cellular signalling pathways [125,178]
E¡ects on elaboration of cytokines and growth factors from
type II cells [179]
Inhibition of surfactant secretion from isolated type II cells
[118^120]
Enhancement of surfactant uptake into isolated type II cells
[152]
Alveolar macrophage receptor binding [38,130^132,140,158,
180^184]
Enhanced alveolar macrophage chemotaxis [160]
Alveolar macrophage activation, elaboration of toxic oxygen
species, NO etc. [156^159,185]
Stimulation of release of cytokines, growth factors, proteases
etc. from alveolar macrophages [141,186,187]
Microbial binding, osponization, phagocytosis
[122,129,154,158,161,163,188^191]
Lipopolysaccharide binding/regulatory molecule [33,34]
Lymphocyte receptor binding [35]
Reduced lymphocyte proliferation and cytokine expression [165]
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carbohydrate-linked beads and Ca2, except substi-
tution at Arg197 which had no e¡ect [46]. Mutagen-
esis experiments were performed in which the
Glu195^Pro196^Arg197 (EPR) sequence of rat SP-A
was substituted with Gln195^Pro196^Asp197 (QPD)
[45]. As was predicted based on the results of similar
experiments performed with MBP-A [55], these mu-
tations increased the binding of SP-A to galactose.
These experiments con¢rmed that the carbohydrate
binding site of SP-A maps to the region predicted by
homology with MBP-A and con¢rmed a role for the
EPR sequence in the determination of sugar binding
speci¢city of SP-A. The alanine mutant SP-As and
the QPD protein have proven to be useful tools to
dissect the role of the CRD in several of the reported
functions of the protein (see below).
SP-A binds speci¢cally to high mannose carbohy-
drates that are commonly present on the surface of
microbes but which are not usually found on mam-
malian cells. In bacterial organisms, these sugars are
most likely components of lipooligosaccharides or
capsular oligosaccharides [87]. The only reported mi-
crobial glycoprotein ligand for SP-A that is known
to bind via a lectin^carbohydrate interaction is the
major surface glycoprotein (MSG) of Pneumocystis
carinii (Pc) [88]. Pc causes a severe pneumonia in
immunosuppressed humans and laboratory animals
that is consistently associated with an elevation in
the alveolar level of SP-A [89]. The MSGs are a
closely related family of abundant cell surface glyco-
proteins that are thought to be major targets for the
cellular and humoral immune defenses of the host
[90^92]. There are up to 100 similar but distinct cop-
ies of MSG in the Pc genome [93], that are selectively
expressed by translocation to a telomeric expression
site called the upstream conserved sequence (UCS)
[94]. The shuttling of di¡erent genes in and out of
the UCS expression site is thought to result in anti-
genic variation of MSGs that are presented on the
surface of the organism [95,96]. SP-A may function
as a broad spectrum antibody independent opsonin
that assists in the clearance of Pc by lectin mecha-
nism that is not dependent on the recognition of
changing peptide epitopes. In 1992, Zimmerman et
al. reported that MSG was a ligand for SP-A [88].
This conclusion was based on the ¢nding that SP-A
bound to whole Pc in a Ca2- and carbohydrate-de-
pendent manner, and to a protein species in mem-
brane preparations of Pc that had the mobility of
MSG on two-dimensional SDS^PAGE. McCormack
et al. subsequently reported that binding of SP-A to
puri¢ed MSG was reduced by deglycosylation of the
MSG with N-glycanase and blocked by several indi-
vidual point mutations of the Ca2- and carbohy-
drate ligating residues of the CRD [47]. Collectively,
the data indicate that the CRD of SP-A binds to N-
linked carbohydrates associated with MSG, but the
existence of other binding epitopes, such as O-linked
carbohydrate or peptide domains, cannot be ex-
cluded. The importance of SP-A in clearance of Pc
is supported by recent, preliminary evidence that
SP-A de¢ciency results in enhanced susceptibility to
Pc pneumonia in SP-A gene targeted mice [97].
SP-A has also been reported to bind to glycolipids,
several of which have recently been identi¢ed in ex-
tracellular surfactants isolated from rats and hu-
mans. SP-A speci¢cally binds to lactosylceramide
and galactosylceramide on TLC plates or adsorbed
to plastic wells [98]. The structural basis and physio-
logical signi¢cance of glycolipid binding by SP-A re-
mains unclear.
4.3. SP-A^phospholipid interactions
4.3.1. Background
Protein^surfactant phospholipid interactions that
occur at the oil^water interface constitute an impor-
tant yet poorly characterized area of pulmonary
biology. SP-A is a Ca2-dependent phospholipid
binding and aggregating protein, that is intimately
associated with surfactant phospholipids in the
alveolar space. The physiological importance of SP-
A^phospholipid interactions is not fully under-
stood, but several roles for SP-A in surfactant func-
tion have been proposed.
4.3.1.1. SP-A is required for the structure and/or
stability of surfactant aggregates. This is one of
the more thoroughly substantiated of SP-As surfac-
tant roles. Tubular myelin contains large amounts of
SP-A, and SP-A is required to produce tubular mye-
lin forms from puri¢ed surfactant components DPPC
and SP-B, in vitro [99]. SP-A gene targeted animal
models that are de¢cient in SP-A have little or no
tubular myelin [83]. SP-A may drive the formation of
tubular myelin in the extracellular space as the lamel-
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lar body unfolds, or it may stabilize an otherwise
transient lattice structure. In vitro cycling studies
have also provided evidence that SP-A enhances
stability of large surfactant aggregates [100], of which
tubular myelin is a member. Low-speed centrifuga-
tion of the bronchoalveolar lavage sediments the
more surface active large (or dense) surfactant forms,
which can be converted to the inactive, less sediment-
able, ‘light’ forms by cycles of surface expansion and
compression in vivo (i.e., with respiration) [101] or
by tumbling in a football shaped vessel in the labo-
ratory [102]. SP-A retards large aggregate conversion
in vitro and in vivo, suggesting that the protein may
play a role in maintaining a surface-active surfactant
pool [103]. The role of individual structural domains
of SP-A in this activity has not been examined.
4.3.1.2. SP-A protects the surface activity of sur-
factant ¢lms. Acute lung injury results in the £ood-
ing of the alveolar space with serum proteins that
directly interfere with the function of surfactant
[104^106]. SP-A blocks foreign protein-induced in-
hibition in vitro [107] and in vivo [108]. Recently,
surfactant isolated from the SP-A gene targeted
mouse was shown to be susceptible to protein inhib-
ition [84]. No structural data are available for the
mechanism of this SP-A function.
4.3.1.3. SP-A augments the adsorption of phospho-
lipids to an air^liquid interface and improves surface
tension of cycled surfactant mixtures, in vitro. Two
lines of in vitro evidence suggest that SP-A may play
a role in the assembly and re¢nement of surfactant
¢lms. Hawgood et al. reported that SP-A, in concert
with the hydrophobic surfactant proteins, had a mi-
nor cooperative e¡ect on the adsorption of surfac-
tant phospholipids to an air^liquid interface, in vitro
[109]. Secondly, the addition of small amounts of
Fig. 3. Mapping of domains of SP-A that mediate lipid binding and aggregation by site-directed mutagenesis. Speci¢c amino acid sub-
stitutions and deletions are aligned with a schematic representation of the primary structure of rat SP-A (top left) and with the func-
tional consequences of each mutation (right). Mutations that have been reported include (from N- to C-terminus): individual Ser (S)
substitutions of the two disul¢de forming N-terminal Cys (C) [29,30], deletion the collagen-like domain (open box) [29], substitution
of the SP-D N-terminal segment and collagen domain [113], single [46,47,73] and tandem [45] amino acid substitutions for the SP-A
residues E(Glu)195, R(Arg)197, E(Glu)202, N(Asn)214, D(Asp)215 that correspond to the Ca2 coordinating residues of MBP-A (see
Fig. 2), and SP-D [74] and MBP [75] CRD sequences that were substituted for the corresponding segments in SP-A. Deletion of the
N- and C-terminal N-linked oligosaccharides had no e¡ect on the functions listed (not shown) [71]. The neck domain (closed box)
and the large (Cys 135^Cys 226) and small (Cys 204^Cys 218) intramolecular disul¢de loops are also shown.
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SP-A enhances the e¡ect of cycling on the reduction
in minimum surface tension of surfactant ¢lms ad-
sorbed to the surface of an oscillating air bubble
[107]. Recent evidence that the collagen-like domain
and the CRD are both required for the surface ten-
sion lowering e¡ects of SP-A are discussed below. It
is not clear that these in vitro surface active proper-
ties of SP-A are physiologically relevant in the lung,
however. Surfactant replacement reagents which con-
tain no SP-A are e¡ective therapies for infant respi-
ratory distress syndrome [110], and SP-A gene tar-
geted animals have normal lung compliance and only
subtle abnormalities in surfactant function [83]. It is
possible that SP-A plays a role in the surface tension
lowering properties of surfactant which only become
manifest in the presence of speci¢c stressors.
4.3.2. The role of individual SP-A structural
domains in the phospholipid binding,
liposome aggregation and surface
tension lowering e¡ects of SP-A
The structural requirements for the speci¢c bind-
ing of SP-A to phospholipids have been determined
using ligand blots of informative phospholipid spe-
cies and mutagenesis of the protein (Fig. 3).
4.3.2.1. Phospholipid structural determinants for
SP-A binding. SP-A binds avidly to dipalmitoyl-
phosphatidylcholine (DPPC) but less strongly to
phosphatidylcholine, indicating that saturated fatty
acid side chains are important in the interaction
[111]. Sphingomyelin is also a preferred ligand but
SP-A does not bind to the other major phospholipid
components of surfactant including phosphatidyl-
glycerol, phosphatidylinositol, phosphatidylethanol-
amine or phosphatidylserine. Binding is retained by
dipalmitoylglycerol but not by palmitic acid or lyso-
phosphatidylcholine, suggesting that two adjacent
glycerol-coupled fatty acid chains are required for
the interaction. The speci¢city of the polar head
group also plays an important role in the binding,
since SP-A does not bind to dipalmitoylphospha-
tidylglycerol.
4.3.2.2. SP-A structural determinants for phospho-
lipid binding and aggregation. The mapping of the
phospholipid interaction domain of SP-A has been
addressed in several mutagenesis studies. Early re-
ports suggested that the lipid binding site of SP-A
was located in the neck region of the protein, a con-
cept that was consistent with the hydrophobic nature
of this domain [112]. The ¢nding that a chimeric
collectin composed of the N-terminal region+colla-
gen domain of SP-D and the neck+CRD of SP-A
bound to DPPC also supported the existence of a
lipid binding site in the C-terminal domains of SP-
A [113]. However, characterization of a mutant SP-A
with tandem mutations in the CRD (Glu195Gln, Ar-
g197Asp) revealed that the liposome aggregation
function of SP-A was lost, implicating the CRD
rather than the neck as the major lipid interaction
site [47]. This notion was also supported by a study
by Kuroki et al., who found that both lipid binding
and aggregation were blocked by a monoclonal anti-
body (denoted ID-6) that recognized a epitope near
the C-terminal end of the CRD, but not by a neck
speci¢c monoclonal antibody (denoted 6E3) [39].
Subsequent mutagenesis experiments have shown
that alanine substitutions for the acidic amino acids
that coordinate the Ca2 ion in the carbohydrate
binding site of the CRD (Glu195Ala, Glu202Ala,
Asp215Ala) block lipid binding and aggregation
[46]. Amino acid substitutions for polar (Asn214Ala)
and basic amino acids (Arg197Ala) in that site that
are also thought to form Ca2 coordination had var-
iable but generally less pronounced e¡ects on lipid
interactions. Chimeras made from CRD sequences of
SP-D substituted for corresponding segments in the
C-terminal end of the CRD of SP-A provided addi-
tional information [74]. All SP-A functions and the
ID-6 antibody epitope (Cys 204^Cys 218) were lost
following even the most conservative substitution, a
chimera in which SP-A sequences were replaced with
an SP-D segment corresponding to the ¢rst Ca2-
coordinating residue of the carbohydrate binding
site through the C-terminus. Seemingly con£icting
results were obtained when highly functional chime-
ras were similarly constructed from MBP-A-CRD
sequences [75]. However, the MBP-A but not the
SP-D peptide segments that were exchanged with
SP-A sequences contained all of the critical amino
acids for coordination of Ca2 in the same positions
as they occur in SP-A (Glu 195, Glu 202, Asn 214,
Asp 215). The Ca2 binding site and the ID-6 mono-
clonal antibody epitope were clearly reconstituted in
the SP-A^MBP-A chimera, probably because the
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SP-A and MBP-A sequences are su⁄ciently similar.
The functional result was nonetheless surprising, be-
cause there are several amino acid di¡erences result-
ing in charge neutralization and inversion in the
reengineered SP-A^MBP-A CRD. Collectively, the
results of the point substitution and chimeric muta-
genesis studies are consistent with the localization of
the major lipid binding site of SP-A to the CRD. The
lipid binding site(s) may overlap with Ca2^carbohy-
drate binding site, or may be located at another site
within the CRD which requires a Ca2-dependent
conformational change to become exposed and/or
active. Precise identi¢cation of the lipid interaction
site is di⁄cult to achieve with mutagenesis experi-
ments alone and will likely require solution of the
structure of the SP-A^lipid complex by x^ray crys-
tallography, as has been accomplished for the phos-
pholipid binding proteins binding proteins BPI [114]
and annexin V [115].
The N-terminal domains of SP-A also play impor-
tant roles in lipid vesicle binding. Mutant recombi-
nant rat SP-As bearing a deletion of the collagen-like
domain or a disrupted N-terminal interchain disul-
¢de bond at Cys6 bind to liposomes only 1/2 and 1/3
as e¡ectively as the wild-type recombinant protein,
respectively [29]. These mutations caused a reduction
in oligomeric mass of the proteins as determined by
gel ¢ltration, albeit to a lesser degree than was an-
ticipated. Our interpretation of these data is that the
binding of SP-A to liposomes is mediated by rela-
tively weak interactions between the CRD and phos-
pholipids at the vesicle^solvent interface, which are
ampli¢ed by the simultaneous binding of several
CRDs from individual oligomers.
The Ca2-dependent aggregation of phospholipid
vesicles by SP-A is a useful model to analyze SP-A’s
role in the formation and stability of surfactant ag-
gregates and ¢lms. The CRD is critical for the lipid
aggregation function of SP-A and, in general, the
e¡ects of various CRD mutations on the lipid bind-
ing and lipid aggregating functions of SP-A closely
parallel one another (e.g., Glu195Ala, Glu202Ala,
Asp215Ala mutations block both lipid binding and
aggregation [46]). However, the ¢nding that the
Glu195Gln, Arg197Asp [45] and the Arg197Asp
[73] mutant SP-As bind but do not aggregate phos-
pholipid vesicles indicates that lipid binding is not
su⁄cient to cause aggregation. The dissociation of
these functions suggests that although the lipid bind-
ing and aggregation domains of SP-A may overlap,
they are clearly not identical. One possibility is that a
speci¢c conformational change in the CRD is re-
quired to e¡ect lipid aggregation once binding has
taken place, a shift that may be disrupted in the
QPD protein. However, recent analyses of the ki-
netics of SP-A liposome interactions using the reso-
nant mirror technique and near-infrared light scatter-
ing supported the sequence; SP-A conformational
change, liposome binding, liposome aggregation
[116]. Another interesting hypothesis that could ac-
commodate the separation of lipid binding and ag-
gregation domains was suggested by Haagsman et al.
[117]. They found that deglycosylation eliminated ag-
gregation by human SP-A, suggesting that crosslink-
ing of SP-A^vesicle complexes occurs by the ligation
of N-linked oligosaccharides of SP-A by CRD do-
mains from neighboring liposomes. In their model,
SP-A must simultaneously bind to liposomes and to
itself, though a lectin^oligosaccharide interaction, to
e¡ect aggregation. This mechanism may not apply to
all species however, since the genetic deletion of car-
bohydrate from recombinant rat SP-A did not block
phospholipid aggregation [71].
The N-terminal domains of SP-A are also impor-
tant for lipid aggregation [29]. Disruption of the in-
terchain disul¢de bond at Cys 6 completely blocks
lipid vesicle crosslinking by SP-A. However, deletion
of the collagen-like domain without disruption of
Cys 6 disul¢de bridge does not a¡ect aggregation.
These data indicate that Cys 6 interchain disul¢de
linkage but not the collagen-like region is required
for aggregation. Preliminary evidence indicates that
the Cys 31 intermolecular disul¢de bridge is much
less critical than Cys 6 for lipid aggregation [30].
4.3.2.3. SP-A structural determinants for enhancing
the surface active properties of surfactant ¢lms. SP-
A has been shown to reduce the minimum surface
tension that surfactant ¢lms can achieve when they
are cyclically compressed and expanded [107]. Re-
cently, we reported that the Cys 6 intermolecular
disul¢de bond but not the collagen domain is re-
quired for this function [29]. The surface tension low-
ering e¡ect of SP-A appears to require a cooperative
interaction between N-terminal domains and the
CRD, since the Glu195Gln, Arg197Asp protein
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also has no e¡ect on surface pressure in the labora-
tory [29]. We speculate that interchain linkage at
Cys 6 is required to maintain the oligomeric structure
of the protein that optimizes CRD interactions with
the phospholipids at the interface, but delineation of
the mechanisms involved will require further experi-
ments.
5. SP-A^type II cell interactions
5.1. Background
SP-A regulates the secretion and uptake of surfac-
tant by isolated type II cells [118,119]. Disruption of
SP-A^SP-A receptor interactions by biochemical
modi¢cations of SP-A or incubation with anti-SP-A
antibodies block surfactant regulation by the protein,
indicating that the two events are coupled [120]. The
inhibitory e¡ect of SP-A on surfactant secretion from
isolated type II cells is not blocked by incubation
with excess monosaccharides [120]. This property is
used as the hallmark of speci¢c inhibition by SP-A,
since other unrelated, nonpulmonary lectins have
been shown to inhibit surfactant secretion by a car-
bohydrate-reversible mechanism [121]. Inhibition of
secretion is maximal at a concentration of 5^10 Wg/
ml SP-A [73,118,119], which is at least 15-fold lower
than the physiological concentration predicted in the
alveolar hypophase [122]. However, almost all SP-A
in the extracellular compartment of the lung is com-
plexed with lipid, therefore the availability of the
protein for physiological cellular interactions is un-
clear. Secretagogues increase the numbers of SP-A
receptors on the cell surface of isolated alveolar
type II cells, suggesting that intracellular pools of
receptors are available for recruitment [123]. The ex-
istence of a high a⁄nity receptor(s) for SP-A on the
surface of type II cells and the coupling of occupancy
of the receptor to a speci¢c e¡ect on surfactant se-
cretion support a role for SP-A in the control of
surfactant phospholipid levels in the alveolar space.
However, an SP-A gene targeted mouse with unde-
tectable SP-A levels had normal surfactant pool sizes
under resting conditions [83]. Further studies will
obviously be required to determine if SP-A is re-
quired for the physiological control of surfactant ho-
meostasis.
Several approaches have been applied to the mo-
lecular characterization of the SP-A receptor on the
surface of type II cells. Strayer identi¢ed a 30 kDa
type II cell membrane SP-A recognition protein
(SPAR) using anti-idiotype antibodies directed
against monoclonal anti-SP-A antibodies [124]. The
SPAR proteins have projected structures which are
consistent with cell membrane receptors, and are ex-
pressed primarily in the lung. The anti-SPAR anti-
body inhibits SP-A receptor mediated Ca2-signaling
and inhibition of secretion from isolated alveolar
type II cells [125,126]. Stevens et al. developed a
type II cell antibody by an auto anti-idiotypic anti-
body technique using SP-A as the antigen [127]. The
antibodies recognize a cell surface SP-A binding pro-
tein that has an apparent mass of 55 kDa (BP55)
under reducing conditions and 170^200 kDa under
nonreducing conditions. The antibody competes for
the binding of SP-A to type II cells, and blocks SP-A
mediated uptake of liposomes by the pneumocyte
[128]. Interestingly, the antibody had no e¡ect on
the inhibition of secretion of surfactant by SP-A,
suggesting that uptake and secretion may be medi-
ated by two separate receptors. Chroneos et al. pu-
ri¢ed a 210 kDa SP-A binding protein from a U937
macrophage cell line using a⁄nity chromatography
with SP-A as the ligand [38]. The 210 kDa protein
was also isolated from rat lung membranes using
ligand and detergent extraction, respectively. The
antibody inhibited the binding of SP-A to type II
pneumocytes by 70% and blocked SP-A mediated
inhibition of surfactant secretion. Interestingly, the
incubation of the anti-SPR210 antibody with isolated
type II cells alone appeared to stimulate the secretion
of surfactant. The binding of SP-A to macrophages
and SP-A mediated phagocytosis of the mycobacte-
rium, BCG, into macrophages were also inhibited by
anti-SP-R210 [129]. The tissue distribution of the SP-
R210 protein has not been reported. Nepomuceno et
al. have cloned and sequenced a 126 000 Mr cell sur-
face protein (denoted C1qRp) from U937 cells that
binds to C1q, MBP-A and SP-A [130]. The C1qRp
contains several interesting domains including a C-
type CRD, ¢ve EGF domains, a transmembrane do-
main and a tyrosine phosphorylation motif. The tis-
sue distribution of this receptor has not been re-
ported and it is not clear if it is expressed on type
II cells. This receptor is clearly distinct from a C1q
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and SP-A binding protein isolated by Malhotra et al.
(C1qR), which has a reduced molecular mass of
60 kDa and signi¢cant homology to calreticulin
[32,131,132]. The C1qR appears to bind to SP-A
and C1q via the N-terminal end of their collagenous
regions. Determination of the importance of each of
these receptors for pulmonary homeostasis may re-
quire ablation by gene targeting.
5.2. Role of individual SP-A structural domains in the
receptor-mediated regulation of surfactant uptake
and secretion by isolated alveolar type II cells
Mutagenesis studies have mapped the SP-A recep-
tor binding and surfactant regulatory functions to
the CRD (Fig. 4). The introduction of tandem muta-
tions into the CRD that altered carbohydrate bind-
ing speci¢city (Glu195Gln, Arg197Asp) blocked
binding to the receptor and the regulation of surfac-
tant secretion and uptake [45]. The substitution of
the Ca2 ligating residues of the carbohydrate bind-
ing site with alanine (Glu195Ala, Glu202Ala, As-
n214Ala, Asp215Ala) had the similar e¡ects on SP-
A’s receptor binding and surfactant regulatory func-
tions [46]. Alanine substitution for Arg 197 was
much less disruptive, consistent with less conserved
nature of this position between SP-As of various
species [73]. Interestingly, the substitution of Arg
197 by His resulted in a protein which retained sur-
factant inhibition and liposome interaction activities
but which did not promote lipid uptake. The disso-
ciation of these two functions suggests that there
may be subtle di¡erences in the domains of the
CRD which mediate inhibition of secretion and up-
take of phospholipid vesicles. Chimeras in which
portions of the CRD of SP-A were replaced with
corresponding sequences from SP-D were inactive
[74], but similarly constructed chimeras made from
MBP-A sequences competed for receptor occupancy
and were e¡ective regulators of surfactant homeosta-
sis [75]. The fact that the MBP-A segments can func-
tionally replace the homologous SP-A sequences is
probably related to the preservation of key residues
in the Ca2 and carbohydrate binding site. Collec-
Fig. 4. Mapping of domains of SP-A that mediate receptor binding and regulation of surfactant secretion and uptake into isolated
type II cells by site-directed mutagenesis. The functional consequences of various reported mutations (Refs. supplied in legend to Fig.
3) of SP-A on receptor binding (recept), inhibition of surfactant secretion from isolated type II cells (inhibit), and enhanced uptake of
liposomes into type II cells (uptake). An asterisk indicates that inhibition of secretion was reversed with excess monosaccharides and
therefore nonspeci¢c. Deletion of the N- and C-terminal N-linked oligosaccharides had no e¡ect on function (not shown) [71]. nd, not
done.
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tively, these studies indicate that the CRD of SP-A
mediates the binding to a receptor population on
isolated alveolar type II cells that controls surfactant
secretion and uptake.
The domains of SP-A that contribute to oligomer-
ic assembly also appear to play an important role in
inhibition of surfactant secretion and uptake. Dis-
ruption of the Cys 6 intermolecular disul¢de bond
blocks surfactant uptake and speci¢c inhibition of
surfactant secretion by type II cells [29], but disrup-
tion of the Cys 31 interchain bond does not appear
to have a major e¡ect [30]. Deletion of the collagen-
like region blocks competitive binding to the SP-A
receptor, speci¢c inhibition of surfactant secretion
and surfactant uptake [29]. Interestingly, deletion of
the collagen-like domain does not a¡ect inhibition of
secretion in the absence of excess carbohydrates (i.e.,
nonspeci¢c inhibition). These data suggest that the
collagen-like region serves a cooperative role in the
interaction with the SP-A receptor, either through a
direct protein^protein interaction or by enhancing
the valency of SP-A for the receptor. It is also pos-
sible that the collagen-deletion mutant form of SP-A
interacts with a separate receptor, perhaps the same
cell surface molecule that mediates Con A-induced
inhibition of surfactant secretion [121].
6. SP-A^lipopolysaccharide interactions
6.1. Background
All higher organisms have developed sensitive
mechanisms for immediate response to infection
with Gram-negative organisms triggered by the bac-
terial cell wall component lipopolysaccharide (LPS
or endotoxin) [33,34]. While there have been major
advances in the understanding of LPS e¡ects in the
systemic circulation, very little is known about regu-
lation of LPS activity in the lung. An ideal system
would discriminate between LPS exposures that her-
ald a legitimate threat, such as pneumonia, and ex-
posures are not signals for infection, such as LPS
inhalation in the absence of bacterial infection. In
the systemic circulation, the activity of LPS is regu-
lated by variety of proteins including LPS binding
serum factors including LBP [133], sCD-14 [134]
and MBP-A [135]; the lysosomal protein BPI [114];
and the membrane receptor CD-14 [136]. It is rea-
sonable to speculate that LPS activity modifying
molecules also exist in the airspace, but they are
not likely to be LBP and sCD-14, since these pro-
teins are present in only trace amounts in the normal
lung [137]. SP-A has emerged as a potential candi-
date as an LPS regulatory protein. This hypothesis is
based on several observations: (1) SP-A binds avidly
to LPS via the lipid A domain [33,34], (2) SP-A ex-
hibits an acute phase response to LPS aerosolization
[138] or intratracheal inoculation [139], (3) LPS up-
regulates the expression of the SP-A receptor on
macrophages [140], and (4) SP-A modi¢es the re-
sponse of AM to LPS [33,141]. Surfactant protein
D is another candidate LPS activity modifying pro-
tein in the lung that also binds to LPS [142] (see
Chapter XV).
6.2. Role of individual LPS and SP-A structural
domains in binding
LPS is a complex glycolipid composed of two dis-
tinct domains [143] that may serve as ligands for
SP-A (Fig. 5). These include hydrophilic repeating
polysaccharides which make up the conserved core
and more variable O-antigen domains, and the
hydrophobic domain called lipid A. The general
Fig. 5. Lipopolysaccharide structure-LPS contains a hydropho-
bic lipid A domain and hydrophilic domains composed of con-
served core polysaccharides and variable polysaccharides. Note
structural similarities with the SP-A ligand, phosphatidylcho-
line. (Drawing from Ref. [114].)
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chemical structure of lipid A from diverse Gram-
negative bacteria is highly conserved and virtually
all LPS-induced biological responses are lipid A-de-
pendent [144]. The structure of lipid A closely resem-
bles that of phospholipids such as phosphatidylcho-
line (Fig. 5), which was incidentally found occupying
the LPS binding site in bacterial permeability-
increasing protein (BPI), a neutrophilic granule pro-
tein that is homologous to LBP [114]. Given that
phosphatidylcholine is a known ligand for SP-A,
and that LPS contains abundant carbohydrate, it is
tempting to speculate that SP-A may bind to one or
both of these domains of LPS via the CRD. The
¢nding that SP-A binds to LPS via the lipid A
moiety in a speci¢c and Ca2-dependent manner is
consistent with this notion [34], although one labo-
ratory found no Ca2-requirement [33] and mannan
or K-D-mannopyranoside did not inhibit binding of
SP-A to LPS. SP-A appears to bind preferentially to
rough LPS, which contains lipid A and two sugar
residues, and not to the more heavily glycosylated
smooth LPS variants [34]. Mutagenesis studies in
progress in several laboratories should elucidate the
structural elements of SP-A that are required for
LPS binding [145].
7. Phospholipase inhibition
Phospholipase A2 (PLA2) is a family of enzymes
that hydrolyzes the fatty acyl group in the sn-2 posi-
tion of phospholipids. In 1991, the primary structure
of a PLA2 inhibitor from the blood plasma of the
Habu snake was isolated and shown to have se-
quence homology with SP-A [146]. This observation
led to a series of experiments to investigate whether
SP-A may play a role in the regulation of PLA2
activity in the lung, especially the synthesis and deg-
radation of surfactant phospholipids in intracellular
and extracellular compartments. Fisher et al. demon-
strated that SP-A inhibits Habu snake PLA2 activity,
by a mechanism that involves a protein^protein in-
teraction [147]. They also reported that SP-A inhibits
a newly characterized Ca2-independent PLA2
present in granular pneumocytes and lung lamellar
bodies but not PLA2 isolated from bovine pancreas
[148,149]. Since SP-A blocked PLA2 activity for lip-
ids that are not ligands for SP-A, it is unlikely that
the e¡ect of SP-A is due to a ligand sequestration
e¡ect as has been demonstrated for other PLA2 in-
hibitors. Further studies will be required to deter-
mine if PLA2 inhibition by SP-A plays a physiolog-
ically relevant role in the lung, and to de¢ne the
structural basis of the interaction between PLA2
and SP-A.
8. Other ligands for SP-A
Annexin IV is a Ca2-dependent phospholipid
binding protein that is enriched in the cytosol of
alveolar type II cells. Annexins are thought to play
an important role in exocytosis. Recently, annexin IV
was shown to be a major SP-A binding protein in the
soluble fraction of bovine lung homogenates [150].
The binding was Ca2-dependent and was preserved
even after delipidation of the protein, indicating a
direct protein^protein binding mechanism. Lung la-
mellar bodies also bound annexin IV, suggesting a
possible role for an SP-A^annexin IV interaction in
lamellar body function. SP-A has also been reported
to bind to cellular myosin [151]. The physiological
relevance of this interaction is not clear, but may
serve to facilitate the clearance of myosin that is
shed into the alveolar hypophase by desquamated
or decaying cells. Finally, SP-A has been shown to
bind to the major outer membrane protein (OMP) of
Hemophilus in£uenza in a Ca2-dependent manner
[87]. The Ca2-dependent binding of SP-A to non-
glycosylated proteins such as OMP suggests that the
CRD of SP-A may recognize peptide ligands.
9. Summary and future directions
The abundance of SP-A in the alveolar space and
the conservation of SP-A across species attest to the
importance of the protein in pulmonary function.
Based on the homology of SP-A with MBP-A, data
from several laboratories demonstrating opsonic and
macrophage activating properties, and the bacterial
clearance defect of the SP-A-de¢cient mouse, it
seems clear that SP-A performs a host defense role
in the lung. The presence of a high a⁄nity receptor
for SP-A on alveolar type II cells, the speci¢c binding
of SP-A to surfactant phospholipids, the e¡ects of
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SP-A on the assembly, integrity and surface activity
of surfactant ¢lms, and the demonstrable surfactant
function abnormalities in SP-A gene targeted mice
suggest that SP-A may also be an important protein
for surfactant function. A recurring theme from
structural studies of SP-A is that the CRD is the
predominant ligand binding domain for Ca2, carbo-
hydrates, lipids and cell surfaces, and that the N-
terminal domains support the multivalent, oligomeric
structure required for high-a⁄nity interactions. Ad-
vances in the understanding of the structure^function
relationships of SP-A will be greatly facilitated by the
solution of its crystal structure, both as an apopro-
tein and complexed with its biological ligands. Ulti-
mately, validation of the physiological relevance of
each proposed SP-A function will require testing in
natural and genetically engineered animal models.
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